Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Pulmonx CorporationNASDAQ: LUNG
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $10.11M (cash outflow) fell 25.3% year over year, behind the -14.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 42.4% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.
Context
- Free cash flow amounted to 36.4% of revenue in FY2025, down 3.0 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.3% toward the trailing-twelve-month pace of -14.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (32.9M) USD
- Year-over-year change
- +0.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.9M) | +0.3% |
| FY2024 | 2024-12-31 | (32.98M) | +14.1% |
| FY2023 | 2023-12-31 | (38.42M) | +17.3% |
| FY2022 | 2022-12-31 | (46.45M) | -3.0% |
| FY2021 | 2021-12-31 | (45.1M) | — |
Free Cash Flow vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 free cash flow of $29.46M is the 7th largest of the 10 companies compared; the peer median is $42.79M.
- Its year-over-year change of -14.0% is the 7th highest of 10, against a peer median of -5.5%.
- Free cash flow amounts to 33.3% of revenue for LUNG, versus a peer median of 39.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.96M | +0.9% | +25.5% | 1367.7% | |
| LTM Mar 2026 | $81.45M | -1.7% | +9.6% | — | |
| LTM Mar 2026 | $75.02M | +40.4% | +0.9% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $66.29M | -5.5% | +26.5% | — |
| LTM Mar 2026 | $42.79M | -24.7% | -23.9% | — | |
| LTM Jun 2026 | $31.62M | -8.8% | -12.4% | 39.6% | |
| LTM Mar 2026 | $29.46M | -14.0% | -10.9% | 33.3% | |
| LTM Mar 2026 | $28.66M | -20.9% | -26.4% | 187.0% | |
| LTM Mar 2026 | $14.8M | +143.9% | — | 5.8% | |
| LTM Mar 2026 | $7.08M | -211.3% | — | 6.9% | |
| Peer median (excluding LUNG) | $42.79M | -5.5% | +0.9% | 39.6% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Depreciation & Amortization | 3.16M | 4M | 1.55M | 1.49M | 1.15M |
| Deferred Income Tax | (6K) | 49K | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 22.1M | 22.96M | 0 |
| Change in Working Capital | (7.84M) | (7.06M) | (2.56M) | (1.7M) | (1.93M) |
| Accounts Receivables | (2.43M) | (2.19M) | (3.1M) | (1.31M) | 1.08M |
| Inventory | (6.46M) | (3.64M) | 918K | (229K) | (765K) |
| Accounts Payables | 87K | 247K | (345K) | 2.28M | 270K |
| Other Working Capital | 963K | (1.48M) | (27K) | (2.44M) | (2.51M) |
| Other Non-Cash Items | 11.92M | 16.8M | 2.14M | 2.11M | 22.33M |
| Operating Cash Flow | (41.43M) | (45.14M) | (37.61M) | (31.54M) | (32.45M) |
| Capital Expenditures | (3.67M) | (1.32M) | (807K) | (1.45M) | (452K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (52.58M) | (47.19M) | (46.2M) | (27.91M) | (5.65M) |
| Sales of Investments | 10M | 44.28M | 45M | 46.84M | 36.59M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (46.26M) | (4.23M) | (2.01M) | 17.48M | 30.48M |
| Debt Repayment | 0 | (87K) | 19.91M | (95K) | (100K) |
| Common Stock Issued | 4.52M | 2.59M | 0 | 0 | 1M |
| Common Stock Repurchased | (26K) | (27K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.49M | 1.46M | 0 |
| Financing Cash Flow | 4.5M | 2.47M | 21.4M | 1.36M | 903K |
| Effect of Forex Changes | 106K | 145K | 34K | 76K | (92K) |
| Net Change in Cash | (83.08M) | (46.74M) | (18.18M) | (12.62M) | (1.15M) |
| Free Cash Flow | (45.1M) | (46.45M) | (38.42M) | (32.98M) | (32.9M) |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.